Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Inclusion criteria

• To participate in the study, all the following inclusion criteria must be met:
• Patients aged 18 years or older
• Written informed consent obtained before participating in the study.
• Patient is willing and able to complete the assessments, including PRO questionnaires, as outlined in this study.
• Diagnosis of RMS per McDonald Criteria (2017) occurred prior to initiation of Ofatumumab.
• Treatment with Ofatumumab is in accordance with the Portuguese indication of Kesimpta® (i.e., treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features).
• Patients that have initiated Ofatumumab up to 12 M prior inclusion in the study OR Patients that are initiating Ofatumumab at the moment of study inclusion.

Exclusion criteria

• To participate in the study, none of the following exclusion criteria must be met:
• Use of investigational drugs during the study, OR between Ofatumumab initiation and inclusion into the study, OR within 5 half-lives of investigational drug before Ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
• Use of high efficacy therapy (including Ocrelizumab, Natalizumab, Mitoxantrone, Rituximab and Alemtuzumab) in both cohorts prior to the initiation of Ofatumumab.